Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytes by Shao-Ju Chien et al.
Chien et al. BMC Complementary and Alternative Medicine  (2015) 15:61 
DOI 10.1186/s12906-015-0583-xRESEARCH ARTICLE Open AccessFulvic acid attenuates homocysteine-induced
cyclooxygenase-2 expression in human monocytes
Shao-Ju Chien1, Te-Chuan Chen2, Hsing-Chun Kuo3,4,5, Cheng-Nan Chen6* and Shun-Fu Chang7*Abstract
Background: Homocysteine and pro-inflammatory mediators such as cyclooxygenase-2 (COX-2) have been linked to
vascular dysfunction and risks of cardiovascular diseases. Fulvic acid (FA), a class of compounds of humic substances,
possesses various pharmacological properties. However, the effect of FA on inflammatory responses of the monocytes
remains unclear. We investigated the regulatory effect of FA on homocysteine-induced COX-2 expression in human
monocytes.
Methods: Peripheral blood monocytes and U937 cells were used for all experiments. Real-time PCR and ELISA assay
were used to analyze the COX-2 mRNA expression and PGE2 secretion, respectively. Specific inhibitors were used to
investigate the mechanism of homocysteine-mediating COX-2 mRNA expression and PGE2 secretion. Luciferase assay,
transcription factor ELISA, and chromatin immunoprecipitation were used to determine the role of nuclear factor-κB in
FA-mediated inhibition of homocysteine effect on monocytes.
Results: The results show that pretreating monocytes with FA inhibited the homocysteine-induced COX-2 expression
in a dose-dependent manner. Stimulation of U937 monocytes with homocysteine induced rapid increases in the
phosphorylation of ERK and JNK; the inhibitor for ERK and JNK attenuated the homocysteine-induced nuclear factor-κB
activation and COX-2 expression. Transcription factor ELISA and chromatin immunoprecipitation assays showed that FA
blocked the homocysteine-induced increases in the binding activity and in vivo promoter binding of nuclear factor-κB
in monocytes.
Conclusions: Our findings provide a molecular mechanism by which FA inhibits homocysteine-induced COX-2 expression
in monocytes, and a basis for using FA in pharmaceutical therapy against inflammation.
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Fulvic acid (FA), a class of compounds of humic sub-
stances, is a mixture of polyphenolic acid compounds
formed through the degradation of organic substances
such as dead plants, microbes and animals by chemical
and biological processes [1]. FA has been reported recently
to have nutraceutical properties and physiological action
on the human body. It is one of the most interesting nat-
urally occurring phytochemicals with its neuroprotective
effect [2,3]. Antimicrobial and anti-inflammatory proper-
ties of FA have also been reported [4,5]. In addition, the* Correspondence: cnchen@mail.ncyu.edu.tw; sfc0415@ym.edu.tw
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unless otherwise stated.FA extracted from peat had an antioxidant activity and an
inhibitory effect on chemical mediator release in basophils
[6]. These results imply that the FA may possess a pre-
dominant role in their biological activity. Although there
are a number of studies on the effect of FA on cellular and
biological functions, the detailed mechanisms underlying
the regulatory effect of FA remain unclear.
The formation of atherosclerotic lesions is regarded
as a process of chronic inflammatory responses [7].
Several risk factors are known to be involved in promoting
atherosclerosis, including smoking, diabetes mellitus,
hyperlipidemia, hypertension, and hyperhomocysteine-
mia. Abnormal elevation of homocysteine levels in the
blood have been reported in patients with hyperhomo-
cysteinemia [8]. Severe hyperhomocysteinemia (plasma
levels of homocysteine greater than 100 mmol/L) isThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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osis and early occlusive vascular disease [9]. Although hy-
perhomocysteinemia has been considered an independent
risk factor for atherosclerosis, the mechanism of causing
vascular damage by homocysteine is not yet understood.
Endothelial dysfunction and activation is one of the key
events in vascular pathology associated with homocysteine
[10]. In addition, oxidative stress, inflammation, and
smooth muscle cell proliferation, are also involved in this
process.
Monocytes are the primary inflammatory cell type that
infiltrates early atherosclerotic plaques. The release of
pro-inflammatory mediators by monocyte-derived mac-
rophages may play a crucial role in atherosclerotic in-
flammatory responses [11]. Cyclooxygenase-2 (COX-2)
is a key enzyme for the synthesis of eicosanoids. COX-2
is considerably expressed in vascular tissues due to the
stimulation of pro-inflammatory factors, such as cyto-
kines, mitogens and lipopolysaccharide [12]. It is evident
that COX-2 in activated monocytes is of particular rele-
vance in inflammation and atherosclerosis [13]. The acti-
vation of macrophages has been previously correlated
with the induction of COX-2. Macrophages expressing
COX-2 are known to produce prostaglandins that have
pro-inflammatory effects, including activating chemo-
taxis, increasing vascular permeability, and promoting
cell proliferation [12]. Since atherosclerosis is a multifac-
torial disease involving a complex array of contributing
factors including monocyte functions and hyperhomocys-
teinemia, it is necessary to investigate the effect of homo-
cysteine on COX-2 gene expression in human monocytes.
In the present study, we investigated the roles of FA in
modulating homocysteine-induced COX-2 expression
in primary human blood monocytes and human mono-
cytic U937 cells, and also the molecular mechanisms
underlying the regulatory effects.
Methods
Materials
All culture materials were purchased from Gibco (Grand
Island, NY, USA). FA was supplied as a 20% solution by
Esther Material Technology Co., Ltd., Kaohsiung, Taiwan.
PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), and
SB203580 (p38 inhibitor) were purchased from Calbiochem
(La Jolla, CA). Mouse monoclonal antibodies (mABs)
against ERK1/2, JNK1/2, phospho-ERK1/2, phospho-
JNK1/2, and NF-κB p65 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Pyrrolidine dithiocarba-
mate (PDTC), SN50, and other chemicals of reagent grade
were obtained from Sigma (St. Louis, MO).
Cell culture
Human monocytes from the buffy coat (Taiwan Blood
Center, TBSF, Taiwan) were isolated as previouslydescribed [14]. Peripheral blood mononuclear cells (PBMCs)
were isolated by Histopaque 1077 density-gradient centrifu-
gation. Monocytes were purified from PBMCs by negative
selection using the magnetic-activated cell sorting (MACS)
monocyte isolation kit (Miltenyi Biotech, Auburn, CA). The
human monocytic cell line U937 was obtained from the
Bioresources Collection and Research Center (BCRC)
of the Food Industry Research and Development Institute
(Hsinchu, Taiwan). Cells were maintained in RPMI-1640
medium supplemented with 10% FBS.
Real-time quantitative PCR
Real-time PCR was performed, and products were detected
using an ABI Prism 7900HT with the FastStart DNA SYBR
Green I kit (Roche Diagnostics GMbH, Mannheim,
Germany). The designed primers in this study were
COX-2 forward primer, 5′-CTGAA AGATG GACGC
TCAAT-3′; COX-2 reverse primer, 5′-CGTTT CAGAA
GCCAG AAGAG-3′; 18S rRNA forward primer, 5′-
CGGCG ACGAC CCATT CGAAC-3′, 18S rRNA reverse
primer, 5′-GAATC GAACC CTGAT TCCCC GTC-3′.
Quantification was performed using the 2−ΔΔCt method
[15]. All samples were measured in duplicate. The average
value of both duplicates was used as the quantitative value.
PGE2 assay
The levels of PGE2 in the conditioned media were deter-
mined by using the PGE2 ELISA assay kit (R & D Systems)
according to the manufacturer’s instructions [16].
Western blot analysis
Samples were lysed with a buffer containing 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, and a protease inhibitor
mixture (PMSF, aprotinin, and sodium orthovanadate). The
protein concentration was determined using the Bio-Rad
protein assay kit (Bio-Rad, Hercules, CA). Equal amounts of
total proteins were separated by SDS-polyacrylamide gel
electrophoresis (PAGE) (10% running, 4% stacking), trans-
ferred onto a nitrocellulose membrane, and analyzed using
the designated antibodies and the Western-Light chemilu-
minescent detection system (Bio-Rad).
Luciferase assays
Human COX-2 promoter constructs containing −918/+49
of COX-2 5′-flanking DNA linked to the firefly luciferase
reporter gene of plasmid pGL4 (Promega, Madison, WI)
were used as previously reported.16 DNA plasmids at a
concentration of 1 mg/ml were transfected into DLD-1
cells by Lipofectamine (Gibco). The pSV-β-galactosidase
plasmid was cotransfected to normalize the transfection ef-
ficiency. Values obtained were normalized to the levels of
β-galactosidase in the cell lysates. β-galactosidase activities
were determined with an assay kit and exhibited <20%
variation between samples.
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Nuclear extracts of cells were prepared using nuclear
protein extract kits (Panomics, Redwood City, CA). Equal
amounts of nuclear proteins were employed for quantitative
measurements of NF-κB p65 activation using commercially
available ELISA kits (Panomics).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed following a published protocol
[17]. Briefly, chromatins were sheared by sonication (3 times,
10 sec on, 60 sec off). Precleared extracts were immunopre-
cipitated with rabbit anti-p65 and c-jun antibodies or rabbit
IgG at 4°C overnight. DNA was isolated from precipitated
complexes and analyzed by PCR with the following primers
that amplify the part of the human COX-2 promoters that
contain the NF-κB binding sites: 5′-GCCCT CCCCC
GGTAT CCCAT C-3′ and 5′-AAAAA ATTGC GTAAG
CCCGG T-3′. An aliquot of total input nuclear extract was
used as the loading control.
Statistical analysis
The results are expressed as the mean ± standard error of
the mean (SEM). Statistical analysis was determined using
an independent Student t-test for two groups of data and
analysis of variance (ANOVA) followed by the Scheffe’s
test for multiple comparisons. P values less than 0.05 were
considered significant.
Results
Cytotoxic effect of FA on human monocytes
To examine the effect of FA on the viability of monocytes,
human primary monocytes and U937 cells were treated
with FA at a concentration of 0.5, 1, 5, or 10 μg/mL for
24 h, and the MTT assay was performed. As shown in
Figure 1, there was no significant difference on the cell via-
bility between FA-treated and untreated human primary
monocytes (Figure 1A) and U937 cells (Figure 1B). These
results indicate that the FA used in the present study has




















Figure 1 The effect of fulvic acid (FA) on cell viability of human prima
cells (B) were cultured with the indicated concentrations of FA and incuba
described in the “Methods Section”, and is expressed as a percentage of th
of the mean (SEM) of three individual experiments.FA inhibits homocysteine-induced COX-2 expression in
monocytes
To test the effects of FA on homocysteine-induced COX-2
expression in monocytes, human primary monocytes and
U937 cells were pretreated with FA at concentrations of
0.5, 1, 5, and 10 μg/mL for 4 h, and then stimulated with
homocysteine (200 μM) for 4 h in the presence of FA. The
results from real-time PCR analysis showed that homo-
cysteine induced a significant increase in the monocytic
COX-2 mRNA expression, as compared with the unstimu-
lated cells (Figure 2A for human primary monocytes,
Figure 2B for U937 cells). This increase in COX-2 mRNA
expression was significantly inhibited by pretreating cells
with FA (Figure 2A and B) and the inhibitory effect of FA
is in a dose dependent manner. ELISA assays for PGE2
secretion in conditioned medium showed that the stimula-
tion of monocytes with homocysteine resulted in the in-
crease in PGE2 secretion from the monocytes, as compared
with the unstimulated cells (Figure 2C for human primary
monocytes, Figure 2D for U937 cells). Pretreating mo-
nocytes with FA at a concentration of 1 or 10 μg/mL
reduced the homocysteine-induced PGE2 secretion. This
result shows that the effect of FA on homocysteine-induced
COX-2 gene expression is accompanied by the correspond-
ing changes of the PGE2 release from monocytes.
FA mediates homocysteine-induced COX-2 gene expression
at the transcriptional level
To further determine whether the FA modulations of
homocysteine-induced COX-2 expression are transcrip-
tional events, U937 cells were transiently transfected with
the COX-2 promoter construct containing the promoter
region of COX-2 and the reporter gene luciferase (p918-
Luc), pretreated with FA for 4 h, and then treated with
homocysteine for 4 h. U937 cells treated with homocyst-
eine for 4 h significantly increased the COX-2 promoter
activity by approximately 7.65-fold compared with the un-
stimulated cells (Figure 3). Pretreatment of the cells with
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Figure 2 The effect of fulvic acid (FA) on homocysteine-induced COX-2 mRNA expression and PGE2 secretion in human monocytes.
Human primary monocytes and U937 cells were pre-treated with FA (0–10 μg/mL) for 4 h, and then stimulated with homocysteine (200 μg/mL) for 4 h
(A, B) and 8 h (C, D). Monocytes that were not stimulated with homocysteine were used as controls (CL). (A, B) RNA samples were isolated and subjected
to real-time PCR analysis. Data are presented as fold changes in fluorescent density from CL monocytes normalized to 18S rRNA level of three individual
experiments. (C, D) The PGE2 secretion in conditioned media was determined by ELISA analyses. Data are shown as mean ± standard error of the mean
(SEM) of three individual experiments. *P< 0.05 versus CL monocytes. #P< 0.05 versus homocysteine-stimulated cells without pretreatment of FA.
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results suggest that FA-mediated COX-2 induction by
homocysteine is regulated at the transcriptional level.FA-mediated inhibition of homocysteine-induced COX-2
expression is dependent on MAPK
To determine whether the homocysteine-induced COX-2
expression is mediated through the MAPK-dependent
pathways, human primary monocytes and U937 cells were
incubated with a specific inhibitor for ERK (PD98059,Figure 3 Fulvic acid (FA) modulation of homocysteine-induced
COX-2 expression is a transcriptional event. U937 cells were
transfected with COX-2 p918-Luc promoter plasmid. Cells transfected
with p918-Luc that were not stimulated with homocysteine were used
as controls (CL). COX-2 promoter activity was measured as fold changes
using luciferase assay normalized to β-galactosidase activity from at least
three individual experiments. *P< 0.05 versus CL monocytes. #P< 0.05
versus homocysteine-stimulated cells without pretreatment of FA.30 mM), JNK (SP600125, 20 mM), or p38 (SB203580,
10 mM) for 1 h before and during stimulation with
200 μM homocysteine. The homocysteine-induced COX-2
mRNA expression (Figure 4A) and PGE2 secretion
(Figure 4B) were significantly inhibited by PD98059 and
SP600125, but not by SB203580. Moreover, the phos-
phorylation of ERK and JNK in U937 cells also increased
rapidly after homocysteine stimulation, reaching maximal
levels at 10–30 min (Figure 4C). After these transient in-
creases, phosphorylation decreased to nearly basal levels.
U937 cells treated with FA (1 and 10 μg/mL) for 4 h be-
fore the addition of homocysteine significantly inhibited
the homocysteine-induced ERK and JNK phosphorylation
(Figure 4D). FA itself had no effect on the basal levels of
ERK, JNK, and p38 MAPK phosphorylation in the control
cells (data not shown). These results suggest that the
inhibitory effect of FA on homocysteine-induced COX-
2 expression was attributable to their inhibition in
homocysteine-induced ERK and JNK activation in
monocytes.
FA-mediated inhibition of homocysteine-induced COX-2
expression is dependent on NF-κB
The COX-2 gene contains NF-κB binding elements in its
promoter region [16]. To investigate whether NF-κB is
involved in FA-mediated inhibition of homocysteine-
induced COX-2 expression in monocytes, we examined
the effects of NF-κB inhibitors on the homocysteine-
induced COX-2 expression in human primary monocytes
and U937 cells by using the NF-κB inhibitors SN50 and





Figure 4 The effect of fulvic acid (FA) on homocysteine-induced phosphorylation of MAPKs signal pathways in human monocyte.
Human primary monocytes and U937 cells were kept as CL or stimulated with 200 μg/mL homocysteine for 4 h (A) or 8 h (B). Before being kept
as CL or stimulated with homocysteine, cells were pretreated with PD98059 (PD), SP600125 (SP), or SB203580 (SB) individually for 1 h. (A) All bar
graphs represent folds of CL monocytes and normalized to 18S rRNA. (B) PGE2 secretion was determined by ELISA assay. The results are shown as
mean ± SEM of three individual experiments. *P < 0.05 versus CL. #P < 0.05 versus vehicle control (DMSO) with homocysteine stimulation. (C) U937
cells were kept as CL or stimulated with homocysteine for times indicated. (D) U937 monocytes were pre-treated with FA (0–10 μg/mL) for 4 h,
and then stimulated with homocysteine for 0.5 h. The phosphorylation of ERK and JNK was determined by Western blotting. The results shown
are representative of three independent experiments with similar results.
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PDTC, 50 mM) for 1 h, followed by treatment
with homocysteine for 4 h. The homocysteine-induced
COX-2 mRNA expression (Figure 5A) and PGE2 secretion
(Figure 5B) were significantly reduced by inhibition with
PDTC and SN50, indicating that NF-κB is involved in the
regulation of COX-2 gene induction. To investigate
whether NF-κB binds the COX-2 promoter region in U937
cells, we determined the NF-κB activation by using TF
ELISA assay and IκB phosphorylation analysis. These re-
sults showed that the treatment of U937 cells with homo-
cysteine caused NF-κB p65 activity (Figure 5C) and IκB
phosphorylation (Figure 5D) to increase at 1 h and remain
elevated for at least 4 h. Moreover, pretreating cells with
ERK- or JNK-specific inhibitor significantly attenuated
homocysteine-increased NF-κB p65 activity (Figure 5E). To
confirm these results, ChIP analysis was performed. Immu-
noprecipitated chromosomal DNA with anti-NF-κB p65
antibody was subjected to PCR using primers designed to
amplify the COX-2 promoter region harboring the NF-κB
binding sites. NF-κB p65 indeed bound to the COX-2 pro-
moter region containing the NF-κB sites (Figure 5F). To de-
termine whether FA would mediate the NF-κB p65-DNA
binding activity in the nucleus of monocytes in response to
homocysteine, we performed TF ELISA assays. As shown
in Figure 6A, pretreatment of U937 cells with FA (1 and10 μg/mL) for 4 h decreased the homocysteine-induced
NF-κB-DNA binding activity. To further assess the in vivo
regulation of the binding of NF-κB to the promoter regions
of the COX-2 gene in monocytes stimulated with homo-
cysteine in the presence of FA, we performed ChIP as-
says in U937 cells by using an antibody against p65. The
homocysteine-induced in vivo NF-κB p65 binding to the
COX-2 promoter was significantly inhibited by pretreating
the cells with FA for 4 h (Figure 6B).
Discussion
Homocysteine is thought to be an independent risk fac-
tor for atherosclerosis in human beings. Multifactorial
mechanisms such as oxidative stress and inflammation
have been found to play a role in hyperhomocysteinemia-
induced atherogenesis [18,19]. In addition, previous study
suggested that elevated levels of homocysteine may not dir-
ectly induce atherogenesis, but may instead accelerate ath-
erosclerotic lesion development in combination with other
cardiovascular risk factors [20]. The production of pro-
inflammatory mediators such as COX-2 in monocytes plays
an important role in atherogenesis [21]. However, the
mechanism by which homocysteine regulates COX-2 gene
expression of monocytes remains unclear. Fulvic acid is one
of the most interesting phytocomplex molecules and is




Figure 5 The roles of NF-κB in homocysteine-induced COX-2 mRNA expression and PGE2 secretion. (A) COX-2 mRNA and (B) PGE2 expression
were determined in human primary monocytes and U937 cells pretreated with NF-κB inhibitors PDTC and SN50, and then stimulated with 200 μg/mL
homocysteine for 2 h. All bar graphs represent folds of CL monocytes, mean ± SEM of three individual experiments. *P < 0.05 versus CL. #P < 0.05 versus
DMSO-treated cells with homocysteine stimulation. (C) and (E) NF-κB activation was determined by TF ELISA assays in U937 cells treated with
homocysteine only (C) and both homocysteine and PD98059/SP600125 (E). *P < 0.05 versus CL. (D) The phosphorylation of IκB was determined by
Western blotting. (F) ChIP assays were performed for NF-κB using p65 antibody. The results shown are representative of three independent
experiments with similar results.
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Our present study demonstrates for the first time that FA
can exert inhibitory effects on homocysteine-induced
COX-2 expression in monocytes, thereby possibly serving
anti-inflammatory and atheroprotective functions. This in-
hibitory effect of FA on homocysteine-induced COX-2 ex-
pression was mediated by the ERK/JNK and NF-κB
signaling pathways based on several lines of evidence (Fig-
ure 7). First, pretreatment of human primary monocytes
and U937 cells with FA inhibited the homocysteine-
induced COX-2 expression in a dose-dependent manner.
Second, FA inhibited the homocysteine-induced COX-2
promoter activity. This suggests that the FA-mediated(A)
Figure 6 The effect of fulvic acid (FA) on homocysteine-induced NF-
stimulated with 200 μg/mL homocysteine for 4 h. Before being kept as CL or
4 h. (A) NF-κB activation was determined by TF ELISA assays in U937 cells. *P <
antibody. The results shown are representative of three independent experiminhibition in homocysteine-induced COX-2 expression was
regulated at the transcriptional level. Third, treating cells
with homocysteine induced rapid increases in their ERK
and JNK phosphorylation; the inhibitors for ERK and
JNK attenuated the homocysteine-induced COX-2 ex-
pression. Pretreating U937 cells with FA inhibited the
homocysteine-induced ERK and JNK activation, sug-
gesting that the ERK and JNK pathways were involved
in the inhibitory effect of FA on homocysteine-
induced COX-2 expression. Finally, homocysteine in-
duced the NF-κB p65-DNA binding activity and
in vivo promoter binding of NF-κB in U937 cells. These
increases in the NF-κB activation and NF-κB-promoter(B)
κB activation in U937 monocyte. U937 cells were kept as CL or
stimulated with homocysteine, cells were pretreated FA (0–10 μg/mL) for
0.05 versus CL. (B) ChIP assays were performed for NF-κB using p65
ents with similar results.
Figure 7 Schematic diagram showing the FA structure and the antagonistic effects of FA on homocysteine-induced inflammatory COX2
expression in human monocytes.
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mary monocytes and/or U937 cells with FA.
Monocytes are one of the main cell types that express
COX-2 [23]. Transendothelial migration of monocytes
into the vessel wall is the initial step in the formation of
atherosclerotic lesions. Previous study has indicated that
COX-2 up-regulation was observed in peripheral blood
monocytes from patients with acute myocardial infarction,
suggesting that an acute inflammatory response to acute
myocardial infarction is correlated with COX-2 activation
in peripheral blood monocytes [24]. In addition, the pres-
ence of COX-2 has also been reported in the shoulder re-
gion of atherosclerotic plaques, mainly colocalizing with
macrophages and matrix metalloproteinases, which leads
to vascular remodeling and atherothrombotic syndromes
[25]. The results of this study demonstrate that homocyst-
eine induces both COX-2 gene expression and PGE2 se-
cretion in human monocytes. It has been reported that
homocysteine induced COX-2 expression in murine mac-
rophages by ROS generated via NMDA receptor-mediated
calcium-signaling pathways [26]. In the present study, we
found that homocysteine induced rapid increases in the
phosphorylation of ERK and JNK in U937 cells. Further-
more, a specific inhibitor for ERK and JNK inhibited the
homocysteine-induced COX-2 expression. These results
indicate that the activation of ERK and JNK is critical for
the homocysteine-induction of COX-2. Our present study
further demonstrated that FA has an inhibitory effect on
the homocysteine-induced ERK and JNK phosphorylation,
and COX-2 expression.
The transcription factor NF-κB plays a critical role in
regulating inducible gene expression in inflammatory re-
sponses. NF-κB in the promoter regions of the COX-2 gene
have been shown to be essential for the responsiveness ofthis gene to stimuli [27]. NF-κB dimers are retained in an
inactive form in the cytosol through their interaction with
IκB proteins. The interaction of pro-inflammatory factors
on cells induces phosphorylation and degradation of IκB,
thereby liberating NF-κB dimers that translocate into the
nucleus. NF-κB then binds to DNA at specific κB sites
in the promoter regions that regulate target gene ex-
pression [28]. It has been reported that in hepatic cells,
homocysteine-induced COX-2 expression is mediated
via NF-κB activation [29]. However, whether NF-κB is
involved in regulating the COX-2 expression in human
monocytes in response to homocysteine needs to be
elucidated. The results from the TF ELISA and ChIP
assays of our present study demonstrated that the
homocysteine stimulation increased the in vitro DNA
binding activity and the in vivo COX-2-promoter bind-
ing of NF-κB in monocytes. This activation of NF-κB-
DNA binding activity, induced by homocysteine, could
be significantly inhibited by pretreating monocytes with
NF-κB inhibitors PDTC or SN50, which could also in-
hibit the homocysteine-induced COX-2 expression in
monocytes. Before stimulation with homocysteine, cells
pretreated with FA significantly inhibited the homocysteine-
induced NF-κB-DNA binding activity, as well as in vivo NF-
κB-promoter binding in monocytes. These results suggest
that the homocysteine and FA may share a common path-
way, i.e., NF-κB, in mediating COX-2 expression in
monocytes. Our results indicate that FA exerts an anti-
inflammatory function on monocytes stimulated with
homocysteine. In addition, these results also suggest that
this FA inhibition of COX-2 expression stimulated with
homocysteine may reflect the regulatory roles of FA in
gene expressions in monocytes. The present data suggest
that FA may serve anti-inflammatory and atheroprotective
Chien et al. BMC Complementary and Alternative Medicine  (2015) 15:61 Page 8 of 8functions by inhibiting the pro-inflammatory gene expres-
sion in monocytes in response to homocysteine stimuli.
Conclusion
In conclusion, FA inhibited the expression of COX-2
and production of PGE2 from homocysteine-induced
monocytes. Stimulation of homocysteine in monocytes
resulted in increased phosphorylation of ERK and JNK, and
activation of NF-κB. FA inhibited homocysteine-induced
inflammatory mediator expression by regulating the activa-
tion of these pathways.
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